3933 results about "Efficacy" patented technology

The AI-enhanced cellular modeling and simulation platform is a computational system designed to enhance biomedical research and development and personalized medicine and wellness. This platform integrates simulation modeling, machine learning and artificial intelligence, multi-omics data, and sophisticated data fusion and decision-support techniques to create comprehensive models of cellular systems and processes across multiple scales. It enables researchers and clinicians to simulate complex biological interactions, predict disease progression, and design or optimize treatment strategies or medical devices with improved accuracy and efficacy. The system's architecture allows for integration of various components, including real-time data processing, federated learning, and quantum computing enhancements. From personalized drug discovery and cancer therapies to synthetic biology and epidemiological analysis, this platform offers powerful tools for understanding and manipulating cellular systems and bioengineered systems. By bridging the gap between molecular-level interactions between cells and materials and organism-wide effects, it enables significant advancements in healthcare and biological sciences.

The invention relates to the technical field of clinical experiment data processing, and discloses a clinical experiment data analysis method based on reinforcement learning, and the method comprises the steps: obtaining time sequence physiological parameters and treatment scheme execution state parameters; performing hierarchical feature extraction on the time sequence physiological parameters, constructing a dynamic response feature model, and generating an initial treatment response evaluation model in combination with the execution state parameters; loading risk constraints and curative effect indexes to generate a comprehensive evaluation model, and simulating to obtain strategy regulation and control data; constructing and training a reinforcement learning decision model, and generating a treatment path correction model and initial treatment parameters; obtaining dynamic strategy adjustment information, and constructing a multi-stage optimization model for iterative optimization to obtain optimal treatment path parameters; reasoning a curative effect standard reaching probability based on a real-time model, and adjusting a strategy to realize dynamic curative effect matching. According to the method, the clinical data dynamic analysis and treatment scheme optimization capability is improved, and the method is suitable for precise medical scenes.

Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. A balance of precision and recall can be applied to at least one of a toxicity-related model or an efficacy-related model to configure immunotherapy treatment of a patient and / or cohort of patients. Model output can be evaluated differently depending on a determine patient selection criterion to trigger different actions.

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine prescription efficacy quantification method and system.The method comprises the steps that chemical component spectrums, pharmacodynamic substance contents and biological activity indexes of traditional Chinese medicines forming a prescription are obtained; constructing a multi-target regulation and control network by combining a traditional Chinese medicine-target interaction database according to the chemical component spectrum, the pharmacodynamic substance content and the biological activity index, identifying a core efficacy pathway cluster by adopting a Louvain algorithm, and calculating a pathway activation intensity value by adopting a pathway target membership weighting model; according to the core efficacy pathway cluster, establishing a mapping relation between the core efficacy pathway cluster and traditional Chinese medicine efficacy terms through ontology and semantic mapping, and according to pathway activation intensity values, generating a prescription efficacy intensity vector through a weighted aggregation model; according to the efficacy intensity vector of the prescription, verifying and correcting the network weight through an in-vitro cell model, and generating the efficacy quantification of the prescription in combination with the clinical syndrome calibration coefficient. Therefore, the problems of single data dimension and insufficient quantification result accuracy in the prior art are solved.

The invention discloses an AI-driven disease diagnosis and curative effect monitoring analysis system, which comprises a data processing module used for collecting multi-source diagnosis and treatment data and constructing a multi-modal sample set; the diagnosis prediction module is used for generating a diagnosis label, a diagnosis confidence value and a prediction curative effect trend through a multi-task learning model; the curative effect comparison module is used for collecting actual curative effect data, constructing a curative effect observation sequence and generating a curative effect deviation sequence based on the curative effect observation sequence and the predicted curative effect trend; the credibility evaluation module is used for executing credibility review based on the curative effect deviation sequence and the diagnosis confidence value; and the path evolution module is used for recording continuous multi-round diagnosis correction results, generating a jump type diagnosis path and updating a diagnosis and treatment data chain. The dynamic closed-loop verification mechanism between the multi-mode diagnosis and treatment data and the predicted curative effect trend improves the accuracy of disease diagnosis, the reliability of curative effect prediction and the adaptability of the diagnosis and treatment process.

The invention relates to the technical field of electronic prescriptions, in particular to a dynamic electronic prescription generation method and system based on artificial intelligence. The method comprises the following steps: collecting the latest physiological state parameter flow of a patient, carrying out real-time health state evaluation, and generating a personalized patient state map; historical medical records of a patient are extracted, time sequence pathological evolution tracking is carried out, and a pathological evolution trajectory is generated; performing multi-parameter time sequence difference comparison calculation and drug curative effect quantitative evaluation based on the personalized patient state map and the pathological evolution trajectory to obtain a curative effect evaluation report; performing allergic drug identification on the patient based on the historical medical record of the patient, and performing secondary drug screening to obtain a drug candidate set; and performing intelligent matching calculation on the drug candidate set according to the curative effect evaluation report, and performing combinatorial optimization analysis to generate a final effective electronic prescription. The electronic prescription is automatically updated and adjusted based on the state change of the patient, the risk of allergic prescriptions is reduced, and the safety of the prescriptions is improved.

The invention provides a drug relocation method and a drug relocation system. The method comprises the following steps: predicting an expression profile of a drug after cell line disturbance according to a chemical structure of the drug, dose information of the drug and an undisturbed expression profile. And calculating the differential expression profile of the gene in the cell line based on the expression profiles before and after the cell line is disturbed by the drug. And for each drug, according to the differential expression profiles of the genes, calculating an average value of the differential expression profiles of the genes after the drugs disturb different cell lines, and sorting the genes based on the average value to obtain a sorting list of the differential expression profiles of the drugs. And according to the gene characteristics of the target disease and the sorting list, calculating the enrichment score of each drug on the target disease, and according to the enrichment score, evaluating the potential efficacy of the drug on the target disease. The drug relocation method provided by the invention can be used for giving disease specific gene characteristics for drug library screening.

The invention discloses a multi-effect repair type collagen and application thereof, and belongs to the technical field of synthetic biology. Transdermal peptide TD-1, a transmembrane region of human XVII type collagen, an extracellular sixteenth non-collagen region, an extracellular fifteenth collagen region and a coding gene of a His tag are selected to be connected in series, and a gene sequence is optimized through pichia pastoris codon selection preference; and then the T-COL17R3 is constructed and expressed to obtain the T-COL17R3. Efficacy experiments prove that compared with similar products sold in the market, T-COL17R3 not only has excellent transdermal performance, but also has better cell proliferation and migration promoting capability, better capability of resisting early saccharification product ketoamine and later saccharification product dicarbonyl compounds, better capability of scavenging free radicals and resisting elastase, and can be used for preparing the anti-epidermal drug. In addition, synthesis of melanin in B16-F10 cells can be reduced, so that T-COL17R3 has excellent application potential in development of pharmaceutical compositions or skin care products with repairing, anti-wrinkle and firming or whitening and brightening effects.

The invention relates to the technical field of knowledge maps, in particular to a multi-task hepatitis B drug screening method and system based on knowledge map assistance, and the method comprises the following steps: based on hepatitis B virus genotype sequence data recorded along with time, patient drug use records and drug sensitivity. According to the method, virus genotype sequence data, patient drug use records, drug sensitivity and other multi-dimensional dynamic time sequence data are integrated, interaction events between entities are marked through timestamps, and virus variation tracks, drug curative effect changes and other dynamic characteristics are embedded into atlas node attributes; and the knowledge representation can reflect the time dependence in a real scene. A hyperedge connection multi-entity set is defined based on biological pathway annotation information and protein interaction data, the limitation that only a binary relation is supported in a traditional knowledge graph is expanded, a drug combination and multi-target synergistic effect mechanism is explicitly modeled, and misjudgment of the combination effect caused by simplification of the interaction relation is avoided.

The invention relates to a bionic exosome for anti-inflammation and repair as well as a preparation method and application thereof, and belongs to the field of cosmetics. The bionic exosome provided by the invention comprises a membrane structure and an internal load phase, the membrane structure comprises a phospholipid bilayer, a stabilizer and a targeting ligand; the internal load phase comprises a solvent and an active component; the phospholipid bilayer is composed of phospholipid compounds; preferably, at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound, and at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound; at least one of cholesterol, phytosphingosine and sodium stearoyl glutamate is preferably adopted as a stabilizer, so that the stabilizer of the obtained bionic exosome is improved, and the bionic exosome has the advantages of high encapsulation efficiency, good encapsulation efficiency stability, simplicity in operation, excellent anti-inflammatory and repairing effects and the like.

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The invention provides a drug screening and curative effect evaluation method and system based on a glioma organ-like model, and relates to the technical field of biological material analys.The method includes the steps that a three-dimensional fluorescence image of the glioma organ-like model is collected, signal intensity analysis and compensation processing are carried out, a growth feature mapping model is constructed, and the three-dimensional fluorescence image of the glioma organ-like model is obtained; and phenotypic characteristics for representing the glioma organoid heterogeneity are obtained. Inputting the phenotypic characteristics into a drug response evaluation network, and calculating a drug sensitivity score; the drug molecular feature library and the drug collaborative analysis model are combined, the synergistic interaction index of different drug combinations is calculated, the optimal drug combination is screened, the drug administration dosage and the drug administration time sequence are determined in combination with phenotypic features, and finally an individualized treatment scheme is generated. According to the invention, the curative effect of the drug on the glioma organs can be effectively evaluated, and the optimal drug combination and administration scheme can be screened out, so that the accuracy and effectiveness of glioma treatment are improved.

The invention discloses an anesthesia strategy generation system fusing time sequence data and a knowledge graph, and relates to the technical field of medical information processing. The method specifically comprises the steps that five types of vital sign data including arterial blood pressure, electrocardio and electroencephalogram are collected, correction is conducted in combination with traction marks and electrotome interference characteristics, and an analysis result is output; the inference analysis module executes double-track processing based on the analysis value, one track evaluates cortical suppression, shock and ventilation risks and generates a risk report, and the other track performs reverse arbitration when the blood oxygen data is abnormal; constructing a knowledge graph fusing the efficacy nonlinear cooperation equation, the age sensitive parameters and the drug administration sequence influence; and the strategy generation module integrates the multi-source data to generate a drug execution track, and executes fast and slow closed-loop regulation and control based on a risk report and an arbitration result. According to the invention, the adaptation capability of the system to individual differences, the abnormal signal identification and processing capability and the intelligent response level of the anesthesia strategy are improved, and the accuracy and safety of clinical anesthesia are significantly enhanced.

The invention provides a novel anti-human DKK-1 monoclonal antibody, aiming at solving the problems that osteoporosis antibody drugs developed in China at present are biosimilar drugs, and the existing antibody drugs also have certain defects, for example, Romosozumab is easy to cause cardiovascular adverse reactions, and DKK-1 antibody drugs aiming at osteoporosis do not appear on the market globally. According to the present invention, the rarely researched DKK-1 is adopted as the target spot to research the humanized DKK-1 antibody, such that the foundation is laid for the clinic and the effectiveness of the DKK-1 antibody, the treatment approach with the excellent effect is provided for the patient, and the problem of the lack of the innovation of the domestic antibody drug for treating osteoporosis can be hopefully solved.

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

The invention discloses a high-transdermal recombinant humanized XVII type collagen as well as a preparation method and application thereof, and belongs to the technical field of synthetic biology. According to the preparation method, transdermal peptide TD-1, different functional fragments of human XVII type collagen and coding genes of His tags are selected to be connected in series, gene sequences are optimized through pichia pastoris codon selection preference firstly, and then the high-transdermal recombinant humanized XVII type collagen is obtained; and then the recombinant humanized XVII type collagen T-COL17-NC16 and the recombinant humanized XVII type collagen T-COL17 are constructed by expression of the recombinant humanized XVII type collagen T-COL17. Effect experiments prove that compared with similar products sold in the market, the skin-care product has more excellent transdermal performance, can improve cell proliferation and migration ability, also has obvious ability of resisting early saccharification product ketoamine and late saccharification product dicarbonyl compounds, better ability of scavenging free radicals and resisting elastase, and can be used for preparing the skin-care product. Moreover, synthesis of melanin in B16-F10 cells can be reduced, and the compound is expected to become a novel functional biological raw material to be applied to the fields of pharmaceutical compositions or skin care products and the like.

The invention discloses a traditional Chinese medicine diagnosis and treatment aided decision-making method and system, and relates to the technical field of traditional Chinese medicine intelligent diagnosis and treatment aided decision-making, and the method comprises the steps: carrying out the wavelet transformation analysis of pulse condition waveform time series data, extracting a pulse condition dynamic change feature sequence, inputting a tongue image color change rate and a pulse condition feature change rate into a space-time convolution network, and obtaining a time-space convolution network; generating a tongue pulse dynamic association index and outputting a preliminary syndrome classification; fourier transform analysis is carried out on the spleen channel acupoint impedance spectrum, false-true state judgment is carried out in combination with tongue pulse dynamic correlation indexes, preliminary syndrome classification is corrected, and a false-true state quantification result and corrected syndrome classification are output; and matching the corrected syndrome classification with the traditional Chinese medicine knowledge map, adjusting the dosage according to a virtual-real state quantification result, reversely verifying the drug-syndrome specificity through a curative effect database, screening an optimal treatment scheme, and outputting a personalized diagnosis and treatment scheme. According to the method, the syndrome classification precision is improved, and an objective basis is provided for personalized dose adjustment.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The application describes the first-in-human study on using a anti-KLK2xCD3 bispecific antibody and another anti-cancer drug, in particular, in particular a taxane chemotherapy or Androgen Receptor Pathway Inhibitor (ARPI), to provide enhanced antitumor efficacy with a deeper and more durable clinical response.

The invention relates to the technical field of bioactive peptides, in particular to a novel multifunctional collagen-like tripeptide and application thereof, an amino acid sequence contains multiple combinations, X can be selected from multiple components, 3-methoxy-4-hydroxyphenylalanine and the like are added, and the novel multifunctional collagen-like tripeptide can interact with specific proteins, activate related pathways and play multiple physiological functions and is applied to multiple fields. The collagen-like tripeptide has obvious advantages, innovates component expansion functions, improves the preparation method, improves the efficiency, reduces the cost, is matched with other components in the fields of beauty, health care and medicine, enhances the efficacy, realizes targeted delivery, and brings a new opportunity to related industries.

The invention belongs to the technical field of biological medicines, and discloses a DSH loaded medicine as well as a preparation method and application thereof. The DSH loading type medicine is DNA (Deoxyribonucleic Acid) supramolecular hydrogel loaded with 2, 2, 6, 6-tetramethylpiperidine-1-oxide, and the DSH loading type medicine is a DNA supramolecular hydrogel loaded with the 2, 2, 6, 6- Wherein the DNA supramolecular hydrogel is formed by assembling a Y type DNA monomer and an L type DNA monomer. The DSH loaded medicine has good anti-inflammatory and peroxy free radical removing effects, and can achieve the purpose of treating knee osteoarthritis. In addition, the DSH loaded medicine can be used for reflecting the content of peroxy free radicals in knee joints by detecting the contrast ratio of knee joint images through magnetic resonance, and early diagnosis of knee osteoarthritis is achieved.

Disclosed herein are activatable inactive sonosensitizer compounds, referred to as locked sonosensitizer compounds, designed with a detachable stimuli-responsive tether acting as a trigger or safety, as these compounds restore their inherent sonosensitization activity upon the detachment of the tether. The invention further encompasses pharmaceutical compositions comprising the same, offering a strategic approach to sonodynamic therapy, whereas the compounds and compositions are formulated to be administered and applied under favorable conditions, enhancing their efficacy in the context of therapeutic applications, since the therapeutic methods presented herein are more versatile and efficient compared to presently known SDT methods due to the controlled activation of the sonosensitizer.

System and methods for alerting a healthcare provider to prescribed treatments having reduced or no effectiveness due to genetic composition is provided. A database containing treatments known to have reduced or no efficacy in persons having particular genetic markers is queried to determine whether any treatments prescribed by, or likely to be prescribed by, a healthcare provider to the patient are known to have reduced or no efficacy in persons having the same certain genetic markers as the patient. An alert indicating such information is displayed at a healthcare provider system.

The invention discloses a breast cancer neoadjuvant chemotherapy curative effect prediction method and system, and relates to the medical image processing and analysis technology, and the method comprises the steps: carrying out the Macenko dyeing normalization of a sample HE pathological image of a patient; extracting a tissue region from the normalized sample HE pathological image by using an HEST method; inputting the extracted tissue region into a Prov-GigaPath network, extracting a feature vector of a specified dimension under set parameters, and performing dimension reduction on the extracted feature vector; inputting the feature vectors subjected to dimension reduction into an ABMIL model, and training the feature vectors; and predicting the HE pathological image of the patient based on the trained ABMIL model, and visualizing the prediction result by using the attention score of the trained ABMIL model. According to the method provided by the invention, multi-level complex features such as cellular morphology and tissue structure in the HE image can be automatically mined, and the accuracy and reliability of prediction are greatly improved.

The invention discloses an RWS-based post-market drug effect tracking platform, which comprises a data acquisition layer, a data processing layer and a result analysis layer, and is characterized in that the data acquisition layer is used for acquiring RWS data from different sources, the data processing layer is used for preprocessing the RWS data from different sources, constructing an original data chain based on a block chain technology, and analyzing the result of the original data chain; writing the preprocessed RWS data of different sources into an original data chain for storage; and the result analysis layer is used for acquiring the preprocessed RWS data through the original data chain, analyzing the preprocessed RWS data, constructing a drug tracking knowledge graph, and comprehensively analyzing the drug tracking knowledge graph to obtain an indication distribution result, an adverse reaction monitoring result, a treatment cost distribution result and a curative effect analysis result.

The invention relates to application of a platelet reaction protein 4 in preparation of an alopecia medicine, and belongs to the field of medical biology. The invention aims to solve the technical problems of limited curative effect, obvious side effect and narrow application range of the existing alopecia treatment medicine. The invention provides an application of a platelet reaction protein 4 (THBS4) in preparation of an alopecia medicinal preparation, which can promote hair follicles to be converted from a resting period to a growing period by regulating and controlling a mechanical microenvironment around the hair follicles, enhancing the interaction between fibroblasts and hair follicle stem cells and activating regeneration signal channels in hair papilla and hair bud areas. The traditional Chinese medicine composition breaks through the limitation that existing treatment only aims at specific alopecia types, and can be widely applied to various alopecia diseases such as androgenetic alopecia, pressure alopecia and alopecia after chemotherapy. And compared with the traditional medicine, the traditional Chinese medicine composition has the advantages of quick response, no skin irritation reaction and improved hair follicle regeneration efficiency, and provides a brand new solution for safe and efficient treatment of alopecia.

The present disclosure, in some aspects, provides one or more biomarkers (e.g., plasma biomarkers or circulating biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., plasma biomarkers or circulating biomarkers) described herein is regulated by DUX4. Methods (e.g., non-invasive methods) of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided. The present disclosure, in other aspects, provides one or more biomarkers (e.g., transcriptome biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., transcriptome biomarkers) described herein is regulated by DUX4. Methods of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided.

The present disclosure relates to a method for ameliorating or treating malignant ascites using an anti-EpCAM × CD3 bispecific antibody and a composition thereof and use of the anti-EpCAM × CD3 bispecific antibody and a composition thereof in ameliorating or treating malignant ascites. The present disclosure features better dosing convenience, longer dosing intervals, longer dosing cycles, and improved efficacy and safety.